Diagnostics

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.

A cub’s rescue reveals more than a conservation win; it showcases China's massive investment in 'ecological civilization' as a core economic strategy.

A new point-of-care PCR test is moving closer to reality in India, promising to revolutionize the fight against tuberculosis and cervical cancer.

A new flooring finish promises unprecedented durability and safety, transforming high-traffic commercial spaces from clinics to retail boutiques.

The ADA’s new standards push for tech from day one and holistic care, but can the system deliver this innovative future to every patient?

75% of employees say pet health impacts their work stress. Discover why pet benefits are no longer a perk, but a key strategy for productivity and talent retention.

After crossing $1B in assets, a community bank adds a healthcare PE expert to its board. This is more than a hire—it's a new strategy for growth.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

A new dermatology clinic opens in rural Vermont, a case study in corporate-backed expansion. But does this new model solve the access crisis for all?

How does a MedTech firm win 'Top Workplace' twice? Echosens proves that a mission-driven culture is the ultimate catalyst for innovation and market leadership.

After two decades under its visionary founder, Oxford Nanopore taps a commercial scaling expert to lead its next chapter of global growth and market dominance.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

Swedish innovator SciBase is overhauling its capital structure with a complex warrant buyback. Is this a strategic masterstroke or a necessary defensive play?

Healthcare tech firm StaffDNA’s title sponsorship of the Cure Bowl is more than a game—it's a calculated move blending branding with a cancer research mission.

Seegene expands to France's lucrative diagnostics market, but the real story is its plan to build an automated, data-driven health intelligence network.

A new alliance aims to streamline at-home diagnostics for pharma, but who is accountable for patient data and safety in this rapidly growing market?

After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?

Beyond the headlines of the G7 tech meeting in Montréal lies a blueprint for Canada's health future, impacting everything from AI diagnostics to local care.

With a clear FDA path for its breakthrough drug, Praxis is set to disrupt the stagnant, multi-billion-dollar essential tremor market.